Clinical Trials Logo

Psychosis clinical trials

View clinical trials related to Psychosis.

Filter by:

NCT ID: NCT02708940 Completed - Depression Clinical Trials

Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs

Start date: February 2016
Phase: N/A
Study type: Interventional

This research project aims to evaluate the feasibility and effectiveness of a new approach to tailored mobile applications using the Chorus Participatory Mobile Framework. PHP and IOP program participants-patients and therapists--will be consented and enrolled by study staff. Study participants will be invited to workgroups specific to their program to discuss the usability of Chorus and be asked to complete surveys on demographics, satisfaction, self-efficacy, and involvement with Chorus and usability of the tool.

NCT ID: NCT02685748 Completed - Schizophrenia Clinical Trials

Aspirin in Young Psychotic Patients

Start date: July 20, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

In this double blind randomized clinical trial the investigators are going to exam influence of adjuvant Aspirin therapy on soft neurological signs (Heidelberg scale), positive and negative symptoms (PANSS), cytokine profile and inflammatory factors, as well as on cognition (MoCA) in young psychotic patients.

NCT ID: NCT02653729 Completed - Psychosis Clinical Trials

Cbt for Psychosis and Affect on Psychosis Symptoms

cbtpaps
Start date: September 2015
Phase: Phase 2
Study type: Interventional

This study aims to examine the effectiveness of cognitive behavior therapy for psychosis in first episode patients and see the outcome of CBT on psychotic symptoms. Because cognitive behavior therapy mostly use in depressive patient to treat the negative thinking pattern Cognitive behavioral approaches in the treatment of psychosis have become more prevalent in recent years for a number of reasons. Evidence has been available for the past two or three decades regarding the success of these techniques with other forms of psychopathology such as depression, anxiety disorders, and medical problems. Anxiety, depression and low self-esteem have been cited as the most common consequences of psychotic disorders. The observation has also emerged that many patients develop their own coping strategies for reducing the frequency, severity, and disruptiveness of their symptoms. There has also been increasing evidence regarding the influence of social environmental factors on the course of psychosis and the development of stress-vulnerability models to explain these relationships. Research suggests that 20 to 50 percent of persons with psychosis who receive neuroleptics continue to experience difficulties related to their psychotic symptoms.

NCT ID: NCT02569307 Completed - Psychosis Clinical Trials

Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States

NAYAB
Start date: October 2015
Phase: Phase 2
Study type: Interventional

This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS. Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to Treatment as Usual in an operationalized ARMS population in Pakistan:

NCT ID: NCT02535923 Completed - Insomnia Clinical Trials

CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes

CBT-I
Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The goal of this project is to develop guidelines for the clinical tailoring of Cognitive Behavioral Therapy for Insomnia (CBT-I) for Veterans with psychotic disorders and insomnia, and to test the acceptability, feasibility, and preliminary efficacy of CBT-I for improving sleep-related functional outcomes in this population.

NCT ID: NCT02531243 Completed - Psychosis Clinical Trials

Computer-Aided Learning for Managing Stress

CALMS
Start date: September 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to learn whether a new family therapy using computer games with biofeedback might help people at clinical high risk for psychosis and their family members learn to experience less stress and have fewer mental health challenges.

NCT ID: NCT02483130 Completed - Psychosis Clinical Trials

Effect of N-acetylcysteine on Brain Glutamate

NAC
Start date: June 2015
Phase: N/A
Study type: Observational

A double-blind, placebo controlled, crossover study to determine whether a single dose of N-acetylcysteine (a nutritional supplement) can reduce brain glutamate levels in patients with a psychotic disorder. Secondary outcomes are to determine the pattern of alteration in brain perfusion and activity following a single dose of N-acetylcysteine.

NCT ID: NCT02481713 Completed - Psychosis Clinical Trials

Improving Adherence to Cognitive Rehabilitation

Start date: December 1, 2015
Phase: N/A
Study type: Interventional

Purpose of study is to evaluate impact of brief motivational interviewing vs. feedback on learning styles in improving attendance to cognitive training

NCT ID: NCT02459210 Completed - Psychosis Clinical Trials

Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis

CLUES
Start date: January 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to test the feasibility of a modification of CET (Cognitive Enhancement Therapy) to address symptomatic and functional difficulties associated with Clinical High Risk for Psychosis (CHR). Cognition for Learning and for Understanding Everyday Social Situations (CLUES) is designed to improve cognitive functioning (e.g., memory, attention, planning, etc.) in order to improve school, work, and social functioning. CLUES includes the following: 1. Computerized cognitive remediation ("exercises") to improve cognition. 2. Social-cognitive skills group designed to teach participants to act wisely in social situations. 3. Individual coaching sessions designed to enhance translation of skills learned from computer exercises and the group into real life. CLUES is based on Hogarty and Greenwald's Cognitive Enhancement Therapy (CET), which was designed for treating individuals with schizophrenia. Research on CET for individuals with schizophrenia has found that CET appears to have helped participants improve cognition and social and work functioning. This study will investigate the feasibility of CLUES for young people who are showing signs of clinical risk for psychosis. Part 1: Preliminary open label trial of CLUES (n=8) to examine preliminary evidence of target engagement (change in cognition and social cognition), to refine assessment and recruitment approaches, to further optimize the treatment manual, and to ascertain feasibility and tolerability. Part 2: Preliminary randomized controlled trial of CLUES vs supportive therapy (ST) + computer games to explore preliminary evidence of efficacy of CLUES vs. the control treatment (n=30).

NCT ID: NCT02449746 Completed - Schizophrenia Clinical Trials

Study of Immunotherapy in Autoantibody Positive Psychosis

SINAPPS-1
Start date: August 2015
Phase: N/A
Study type: Interventional

Psychosis is a mental health problem that causes people to perceive or interpret things differently from those around them, often involving hallucinations or delusions. Psychosis and schizophrenia are common disorders which predominantly affect younger adults. Recently, the investigators discovered that 5-10% of people with psychosis have antibodies in the blood that are capable of targeting the surface of brain cells, specific to the N-methyl-D-aspartate (NMDA) receptor or voltage gated potassium channel complex, which the investigators believe may be causing the problem. Those positive for antibodies may have a problem with their immune system and this may prevent their brain from working normally. This trial aims to test the feasibility of removing or reducing the antibodies in patients' blood, using immunotherapy, and see if this improves symptoms of psychosis. Immunotherapy in this feasibility study will involve giving all patients steroid tablets and half of them will also receive a drug called "intravenous immunoglobulin" whereas the other half will have a procedure called "plasma exchange". The feasibility study is designed to identify which method of immunotherapy is most suitable for use in this patient population. Results from this will inform on the methodology used for a proposed larger randomised control trial.